Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study
DOI:
https://doi.org/10.2340/actadv.v103.12616Keywords:
Psoriasis, Biologics, IL-17, Secukinumab, Ixekizumab, SwitchAbstract
Whether response to an interleukin (IL-17) inhibitor is different in patients with previous exposure to an IL-17 inhibitor compared with patients with exposure to biologics with other cytokine targets remains to be elucidated. Therefore, the aim of this study was to assess whether previous exposure to an IL-17A inhibitor was associated with worse response than exposure to (an)other biologic(s). All patients in the DERMBIO register treated with an IL-17A inhibitor (secukinumab or ixekizumab) were included. With an absolute Psoriasis Area and Severity Index (PASI) ≤ 2 as response, the proportion of responders treated with IL-17A inhibitors was assessed in patients previously treated with another IL-17A inhibitor and compared with patients with previous exposure to (an)other biologic(s), using a χ2 test. In total, 100, 93 and 83 patients with previous exposure to an IL-17A inhibitor and 414, 372 and 314 patients with previous exposure to (an) other biologic(s) were assessed after 3, 6 and 12 months, respectively. No differences in the proportion of patients achieving PASI ≤ 2 were observed between the 2 groups after 3 months (54% vs 57%, p = 0.59), 6months (70% vs 66%, p = 0.42) and 12 months (69% vs 60%, p = 0.14). In conclusion, when treating patients with IL-17A inhibitors the cytokine target of the previous biologic does not appear to affect the response.
Downloads
References
Cui L, Chen R, Subedi S, Yu Q, Gong Y, Chen Z, et al. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol 2018; 62: 46-58.
https://doi.org/10.1016/j.intimp.2018.06.020 DOI: https://doi.org/10.1016/j.intimp.2018.06.020
Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJ. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatol Treat 2018; 29: 569-578.
https://doi.org/10.1080/09546634.2017.1422591 DOI: https://doi.org/10.1080/09546634.2017.1422591
Loft N, Vaengebjerg S, Halling AS, Skov L, Egeberg A. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Dermatol Venereol 2020; 34: 1151-1160.
https://doi.org/10.1111/jdv.16073 DOI: https://doi.org/10.1111/jdv.16073
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo J-L, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol 2012; 148: 463-470.
https://doi.org/10.1001/archdermatol.2011.2768 DOI: https://doi.org/10.1001/archdermatol.2011.2768
Ger T-Y, Huang Y-H, Hui RC-y, Tsai T-F, Chiu H-Y. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis 2019; 10: 2040622319843756.
https://doi.org/10.1177/2040622319843756 DOI: https://doi.org/10.1177/2040622319843756
Notario J, Deza G, Vilarrasa E, Valentí F, Muñoz C, Mollet J, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatol Treat 2019; 30: 424-429.
https://doi.org/10.1080/09546634.2018.1528000 DOI: https://doi.org/10.1080/09546634.2018.1528000
Galluzzo M, Talamonti M, De Simone C, D'Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther 2018; 18: 727-735.
https://doi.org/10.1080/14712598.2018.1481503 DOI: https://doi.org/10.1080/14712598.2018.1481503
Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, De Simone C, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol 2020; 21: 441-447.
https://doi.org/10.1007/s40257-019-00490-2 DOI: https://doi.org/10.1007/s40257-019-00490-2
Megna M, Di Costanzo L, Argenziano G, Balato A, Colasanti P, Cusano F, et al. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study. Expert Opin Biol Ther 2019; 19: 855-861.
https://doi.org/10.1080/14712598.2019.1622678 DOI: https://doi.org/10.1080/14712598.2019.1622678
Schwarz CW, Loft N, Rasmussen MK, Nissen CV, Dam TN, Ajgeiy KK, et al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study. Acta Derm Venereol 2021; 101: adv00579.
https://doi.org/10.2340/actadv.v101.351 DOI: https://doi.org/10.2340/actadv.v101.351
Loft N, Egeberg A, Rasmussen M, Bryld L, Nissen C, Dam T, et al. Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. J Eur Acad Dermatol Venereol 2022; 36: 1284-1291.
https://doi.org/10.1111/jdv.18126 DOI: https://doi.org/10.1111/jdv.18126
Loft N, Halling A-S, Egeberg A, Skov L. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: a systematic review and meta-analysis. J Am Acad Dermatol 2021; 84: 130-138.
https://doi.org/10.1016/j.jaad.2020.07.085 DOI: https://doi.org/10.1016/j.jaad.2020.07.085
Bokor-Billmann T, Schäkel K. No need to change the drug class: ixekizumab-following secukinumab-therapy in psoriasis. J Dermatol Treat 2019; 30: 216-220.
https://doi.org/10.1080/09546634.2018.1506081 DOI: https://doi.org/10.1080/09546634.2018.1506081
Khemis A, Kelati A, Montaudié H, Lacour J-P, Passeron T. Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: a retrospective study evaluating long-term efficacy and safety. J Am Acad Dermatol 2018; 79: 758-760.
https://doi.org/10.1016/j.jaad.2018.03.027 DOI: https://doi.org/10.1016/j.jaad.2018.03.027
Georgakopoulos J, Phung M, Ighani A, Lam K, Yeung J. Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study. J Eur Acad Dermatol Venereol 2018; 33: e7-e8.
https://doi.org/10.1111/jdv.15100 DOI: https://doi.org/10.1111/jdv.15100
Hegazy S, Konstantinou M, Bulai Livideanu C, Tauber M, Paul C. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab. J Eur Acad Dermatol Venereol 2019; 33: e338-e341.
https://doi.org/10.1111/jdv.15630 DOI: https://doi.org/10.1111/jdv.15630
Sherman S, Cohen ES, Amitay-Laish I, Hodak E, Pavlovsky L. IL-17A inhibitor switching-efficacy of ixekizumab following secukinumab failure. a single-center experience. Acta Derm Venereol 2019; 99: 769-773.
https://doi.org/10.2340/00015555-3200 DOI: https://doi.org/10.2340/00015555-3200
Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol 2019; 33: 553-559.
https://doi.org/10.1111/jdv.15288 DOI: https://doi.org/10.1111/jdv.15288
Amschler K, Phillip S, Mohr J, Wilsmann-Theis D, Poortinga S, Gerdes S, et al. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab. Dermatol Online J 2020; 26: 13030/qt11d602x5.
https://doi.org/10.5070/D3262047415 DOI: https://doi.org/10.5070/D3262047415
Enevold C, Loft N, Bregnhøj A, Zachariae C, Iversen L, Skov L, et al. Circulating brodalumab levels and therapy outcomes in patients with psoriasis treated with brodalumab: a case series. JAMA Dermatol 2022; 158: 762-769.
https://doi.org/10.1001/jamadermatol.2022.1863 DOI: https://doi.org/10.1001/jamadermatol.2022.1863
Loft N, Bregnhøj A, Fage S, Nielsen CH, Enevold C, Zachariae C, et al. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. Dermatol Ther 2021; 34: e15106.
https://doi.org/10.1111/dth.15106 DOI: https://doi.org/10.1111/dth.15106
Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther 2021; 34: e14584.
https://doi.org/10.1111/dth.14584 DOI: https://doi.org/10.1111/dth.14584
Sherman S, Zloczower O, Noyman Y, Amitay-Laish I, Hodak E, Pavlovsky L. Ixekizumab survival in heavily pretreated patients with psoriasis: a two-year single-centre retrospective study. Acta Derm Venererol 2020; 100: adv00349.
https://doi.org/10.2340/00015555-3714 DOI: https://doi.org/10.2340/00015555-3714
Gniadecki R, Kragballe K, Dam T, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.
https://doi.org/10.1111/j.1365-2133.2011.10213.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10213.x
Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld L, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol 2015; 29: 1128-1134.
https://doi.org/10.1111/jdv.12768 DOI: https://doi.org/10.1111/jdv.12768
Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, Iversen L, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One 2012; 7: e36342.
https://doi.org/10.1371/journal.pone.0036342 DOI: https://doi.org/10.1371/journal.pone.0036342
Egeberg A, Iversen L, Gniadecki R, Hvid L, Dam T, Bryld L, etal. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis-nationwide results from the DERMBIO registry. J Eur Acad Dermatol Venereol 2017; 31: 1183-1187.
https://doi.org/10.1111/jdv.14200 DOI: https://doi.org/10.1111/jdv.14200
Loft N, Skov L, Bryld L, Gislason G, Egeberg A. Treatment history of patients receiving biologic therapy for psoriasis - a Danish nationwide study. J Eur Acad Dermatol Venereol 2017; 31: e362-e363.
https://doi.org/10.1111/jdv.14156 DOI: https://doi.org/10.1111/jdv.14156
Loft ND, Skov L, Rasmussen MK, Gniadecki R, Dam TN, Brandslund I, et al. Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis. PloS One 2018; 13: e0192010.
https://doi.org/10.1371/journal.pone.0192010 DOI: https://doi.org/10.1371/journal.pone.0192010
Loft N, Skov L, Iversen L, Gniadecki R, Dam T, Brandslund I, et al. Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. Pharmacogenomics J 2018; 18: 494.
https://doi.org/10.1038/tpj.2017.31 DOI: https://doi.org/10.1038/tpj.2017.31
Gniadecki R, Bang B, Bryld L, Iversen L, Lasthein S, Skov L. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015; 172: 244-252.
https://doi.org/10.1111/bjd.13343 DOI: https://doi.org/10.1111/bjd.13343
Egeberg A, Ottosen M, Gniadecki R, Broesby-Olsen S, Dam T, Bryld L, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.
https://doi.org/10.1111/bjd.16102 DOI: https://doi.org/10.1111/bjd.16102
Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol 2018; 98: 335-339.
https://doi.org/10.2340/00015555-2833 DOI: https://doi.org/10.2340/00015555-2833
Loft ND, Egeberg A, Rasmussen MK, Bryld LE, Gniadecki R, Dam TN, et al. Patient-reported outcomes during treatment in patients with moderate-to-severe psoriasis: a danish nationwide study. Acta Derm Venereol 2019; 99: 1224-1230.
https://doi.org/10.2340/00015555-3331 DOI: https://doi.org/10.2340/00015555-3331
Gottlieb AB, Lacour JP, Korman N, Wilhelm S, Dutronc Y, Schacht A, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad Dermatol Venereol 2017; 31: 679-685.
https://doi.org/10.1111/jdv.13990 DOI: https://doi.org/10.1111/jdv.13990
Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, et al. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatol Treat Treatment 2020; 31: 476-483.
https://doi.org/10.1080/09546634.2019.1671577 DOI: https://doi.org/10.1080/09546634.2019.1671577
Mahil S, Wilson N, Dand N, Reynolds N, Griffiths C, Emsley R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol 2020; 182: 1158-1166.
https://doi.org/10.1111/bjd.18333 DOI: https://doi.org/10.1111/bjd.18333
Loft N, Egeberg A, Rasmussen MK, Bryld LE, Nissen CV, Dam TN, et al. Response to biologics during the first six months of therapy in biologic-naïve patients with psoriasis predicts risk of disease flares: a Danish nationwide study. Acta Derm Venereol 2021; 101: adv00357.
https://doi.org/10.2340/00015555-3722 DOI: https://doi.org/10.2340/00015555-3722
Puig L, Dossenbach M, Berggren L, Ljungberg A, Zachariae C. Absolute and relative Psoriasis Area and Severity Indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol 2019; 99: 971-977.
https://doi.org/10.2340/00015555-3245 DOI: https://doi.org/10.2340/00015555-3245
Mason KJ, Barker JN, Smith CH, Hampton PJ, Lunt M, McElhone K, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol 2018; 154: 581-588.
https://doi.org/10.1001/jamadermatol.2018.0183 DOI: https://doi.org/10.1001/jamadermatol.2018.0183
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Nikolai Loft, Alexander Egeberg, Daniel Isufi, Mads K. Rasmussen, Lars E. Bryld, Tomas N. Dam, Kawa K. Ajgeiy, Trine Bertelsen, Lone Skov
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
